Take the Free Diagnostic

Treatment Foundations of Genetics & Molecular Biology

CPR APPLICATIONS FOUNDATION · CHAPTER 1 · TREATMENT

Treatment Foundations of Genetics & Molecular Biology

Use a chapter-level CPR map to organize how mechanism guides intervention, benefit, and predictable tradeoffs.

Supplemental foundation map: this page orients the detailed CPR Applications for Chapter 1. It is not part of the canonical CPR object inventory.

Browse the Foundations Library
CPR Applications framework

Move through Chapter 1

Normal Foundations

Open this layer →

Abnormal Foundations

Open this layer →

Treatment Foundations · You are here

Review this layer →

1.25 · SOURCE CPR FOUNDATION

Concept

Treatment foundations in genetics and molecular biology are based on mechanism reversal. Once the genetic or molecular problem is identified, therapy is chosen by asking whether the disease reflects overactive function, missing function, toxic expression, impaired repair, or abnormal immune recognition.

Pattern

Step 1 often gives the molecular defect and asks what therapy makes mechanistic sense. A gain-of-function mutation is usually treated by inhibition. A loss-of-function mutation requires replacement, restoration, bypass, or compensation. A tumor with defective DNA repair can be treated by exploiting its vulnerability.

Rule

  1. Gain-of-function means inhibit the overactive pathway: fusion kinases, amplified receptors, and activating mutations create excessive signaling that can be blocked.
  2. Loss-of-function means replace, restore, bypass, or compensate: missing protein function may be addressed with enzyme replacement, gene therapy, splicing modification, mRNA therapy, or pathway support.
  3. Repair defects and pathway dependencies create therapeutic vulnerabilities: tumors with a broken repair pathway may depend on another, making synthetic lethality clinically viable.

Applications

  • BCR-ABL fusion kinase in CML → imatinib
  • HER2 amplification in breast cancer → trastuzumab
  • EGFR activating mutation in lung adenocarcinoma → EGFR inhibitor
  • BRAF V600E mutation in melanoma → BRAF inhibitor
  • BRCA1/2 loss with impaired homologous recombination → PARP inhibitor
  • CFTR dysfunction in cystic fibrosis → CFTR modulator therapy
  • ADA deficiency with impaired purine metabolism → enzyme replacement or gene therapy
  • SMN1 loss in spinal muscular atrophy → SMN2 splicing modification or gene replacement

CPR Applications · Active reasoning

Match the molecular lesion to the intervention

Do not choose a molecular therapy from the disease label alone. Identify what is overactive, deficient, misfolded, or selectively vulnerable. Work through each decision before revealing the reasoning. Your responses stay in this page; there is no score or submission.

Decision 1 of 3

Leukemic cells express a constitutively active BCR::ABL1 fusion tyrosine kinase. Which intervention most directly targets the driver mechanism?
Reveal the worked reasoning (also works without scripts)

Best answer: BCR::ABL1 tyrosine kinase inhibition. A kinase inhibitor such as imatinib targets aberrant downstream phosphorylation signaling generated by the fusion.

Transfer: What new evidence would make a specific kinase inhibitor ineffective? A resistance alteration that reduces effective inhibitor binding.

Decision 2 of 3

A patient with cystic fibrosis has a CFTR gating variant known to respond to ivacaftor. Which mechanism fits the targeted treatment?
Reveal the worked reasoning (also works without scripts)

Best answer: Increase the probability that available CFTR channels open. Ivacaftor is a CFTR potentiator: it enhances gating of responsive channels already present at the cell membrane.

Transfer: Would ivacaftor alone automatically treat every CFTR variant? No; clinical eligibility depends on genotype and an approved responsive variant.

Decision 3 of 3

A tumor has pathogenic BRCA1/2-associated impairment of homologous-recombination repair. Why may PARP inhibition selectively impair its survival?
Reveal the worked reasoning (also works without scripts)

Best answer: Blocking complementary DNA-repair functions creates synthetic lethality. PARP inhibition can generate lesions that HR-deficient cells cannot efficiently repair, producing a therapeutic vulnerability in appropriately selected tumors.

Transfer: What could reduce drug response? Restoration of homologous-recombination function or another resistance mechanism.

Explain it back

Contrast the direction of therapy for an overactive kinase, a responsive CFTR gating variant, and a homologous-recombination-deficient tumor.

Compare your explanation with the reasoning checklist
  • Overactive fusion kinase: inhibit its signaling.
  • Responsive CFTR gating defect: potentiate channel opening.
  • HR-deficient tumor: exploit an alternative DNA-repair dependency, subject to clinical eligibility.

Educational mechanism exercises only. These do not establish individual clinical recommendations or psychometric performance.

How to use this foundation map

  1. Read the Concept and identify the organizing mechanism.
  2. Use the Pattern to recognize how the mechanism tends to appear in Step 1-style reasoning.
  3. Restate the Rule without looking, then test whether each application follows from it.
  4. Move to the adjacent foundation layer or use question practice to test transfer.

When applying the organized knowledge to a case or question, pair CPR with the 5P Approach™.

Continue from here

Back to Chapter 1 in the Foundations Library · USMLE Step 1 resources · Interactive CPR demonstration